Last reviewed · How we verify
Upstream Targeting for the Prevention of Atrial Fibrillation: Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
Prospective randomized open-label blinded endpoint (PROBE) 2x2 factorial study of metformin extended release up to 750 mg BID and lifestyle and risk factor modification (LRFM) in CIED patients with at least 1 ≥5 minute episode of AF over the prior 3 months. Randomization will be stratified by pacemaker vs. ICD and rhythm at enrollment (sinus rhythm/atrial paced vs. AF).
Details
| Lead sponsor | Mina Chung, MD |
|---|---|
| Phase | Phase 4 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 175 |
| Start date | 2018-08-24 |
| Completion | 2026-12 |
Conditions
- Atrial Fibrillation
Interventions
- Metformin
- Lifestyle/Risk Factor Modification
Primary outcomes
- Change in AF burden — 1 year
Composite of change from baseline to 1 year of average daily AF burden % after a 3 month blanking period and survival at 1 year.
Countries
United States